ImmunityBio Inc.

Commercial‑stage biotech developing immune‑boosting therapies—cytokine fusions, DNA/vaccine vectors, cell therapies—to target solid/liquid tumors. Lead candidate, FDA‑approved Anktiva, treats BCG‑unresponsive bladder cancer.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 673
HQ: San Diego

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
IBRX	ImmunityBio Inc. Cap: 2.3B	EQUITY	NMS	USD	US45256X1037	Active	📈